Heidi Overton Is As Shifty as a Window
Murray pressed Overton on mifepristone safety and whether IUDs are abortifacients.

SOURCE CHECK
TAP FOR WHYJezebel is an established digital publication with an identifiable author, but this article uses an openly advocacy-oriented tone and provides limited sourcing beyond hearing remarks and a quoted advocacy-group statement. The source type is recorded as unknown, so the score reflects the publisher’s general profile rather than a supplied category.
- Editorial standards — Established publication, though this piece is written in an overtly opinionated style.
- Author attribution — A named author is credited.
- Source diversity — The article includes hearing remarks and an advocacy-group statement but little independent sourcing.
- Source type — The recorded source type is unknown; the publisher is a digital news and culture outlet.
The article offers direct quotations and identifies the hearing and committee, but it is strongly editorialized, relies on a narrow set of sources, and does not present a response from Overton or the administration to the criticism.
HOW WE SCORE ↗The piece gives substantial attention to criticism of Overton and the administration, including a reproductive-rights advocate’s assessment, but offers little counterargument or response. The nominee’s hearing answers appear, though mostly in the context of the article’s negative framing.
- Counterarguments presented — No response from the administration or a supporter of Overton is included.
- Loaded language — Mocking and evaluative phrasing appears throughout.
- Source diversity — Evidence is largely hearing remarks and one reproductive-rights advocacy statement.
- Opinion vs reporting — Reported events are interwoven with strong editorial commentary.
The article strongly criticizes Overton, Trump, and anti-abortion positions, using a mocking headline and loaded language rather than a neutral account. Its framing and choice of sources consistently support that critical perspective.
- Language tone — Uses ridicule and emphatic language, including calling the nominee unqualified and describing the review as a shameless move.
- Headline — The headline is a wordplay insult directed at the nominee.
- Framing — Frames the hearing primarily as evidence of threats to abortion and contraceptive access.
- Source selection — Includes a statement from a reproductive-rights advocacy leader but no countervailing response from the administration or nominee.
At her Senate confirmation hearing, FDA commissioner nominee Heidi Overton declined to state whether mifepristone is safe or whether IUDs are abortifacients. Sen. Patty Murray challenged those answers, which the article presents as raising concerns about Overton’s approach to abortion medication and birth control.
Heidi Overton, President Donald Trump’s pick to lead the FDA, appeared before the Senate HELP Committee for a confirmation hearing. The article says she skirted questions about vaccines, agreed to help with the administration’s re-review of abortion pills, and did not answer directly when asked whether mifepristone is safe or whether IUDs are abortifacients. Overton said the safety review was ongoing and that, if confirmed, she would assess decisions by safety and efficacy standards.
Sen. Patty Murray pressed Overton on those issues and called her answers alarming. The article also says Sen. Josh Hawley spent much of 2024 amplifying a study about mifepristone’s adverse effects, which it reports more than 300 reproductive health researchers later denounced. Reproductive Freedom for All’s president and CEO characterized Trump’s appointments as a strategy to restrict abortion access.
Community verdict
10 VOTESPeople in this story
SWIPE →Questioned FDA commissioner nominee Heidi Overton at the confirmation hearing
President who selected Overton and whose administration initiated the mifepristone re-review
Senator whose promotion of a study is described as preceding the mifepristone re-review
Discussion · 0
Loading comments…


